Bugworks Research Inc.
Bugworks is a clinical stage biopharmaceutical company dedicated to developing affordable, accessible, novel therapies against infectious diseases and cancer. Founded in 2014 and incubated in Bangalore, it focuses on discovering differentiated and affordable small molecule therapeutics for treating recalcitrant tumors and combating antimicrobial resistance (AMR). The company collaborates with globally reputed partners and has a strong leadership team with extensive experience in drug discovery, infectious diseases, oncology, and biotech innovation.
Industries
Nr. of Employees
small (1-50)
Bugworks Research Inc.
Patents
Heterocyclic compounds useful as anti-bacterial agents and method for production thereof
US-10912780-B2
View Details
Heterocyclic compounds useful as anti-bacterial agents and method for production thereof
US-10912780-B2
View DetailsProducts
Clinical‑stage small‑molecule antibacterial candidates (oral and IV)
Targeted small‑molecule development candidates intended to treat multidrug‑resistant Gram‑negative and Gram‑positive infections with both oral and intravenous formulation goals.
Small‑molecule immuno‑oncology therapeutic candidates
Targeted small‑molecule programs addressing immunosuppressed and refractory solid tumours through modulation of tumour microenvironment and immune pathways.
Clinical‑stage small‑molecule antibacterial candidates (oral and IV)
Targeted small‑molecule development candidates intended to treat multidrug‑resistant Gram‑negative and Gram‑positive infections with both oral and intravenous formulation goals.
Small‑molecule immuno‑oncology therapeutic candidates
Targeted small‑molecule programs addressing immunosuppressed and refractory solid tumours through modulation of tumour microenvironment and immune pathways.
Services
Joint research and development agreements to discover and advance small‑molecule candidates for infectious diseases and oncology with public‑health and commercial partners.
End‑to‑end management of preclinical packages, DMPK/PKPD strategy, toxicology planning and coordination of clinical development activities.
Development of drug product formulations (oral and IV) and provision of CMC strategy in collaboration with external partners to generate clinical‑supply material.
Joint research and development agreements to discover and advance small‑molecule candidates for infectious diseases and oncology with public‑health and commercial partners.
End‑to‑end management of preclinical packages, DMPK/PKPD strategy, toxicology planning and coordination of clinical development activities.
Development of drug product formulations (oral and IV) and provision of CMC strategy in collaboration with external partners to generate clinical‑supply material.
Expertise Areas
- Antibacterial drug discovery
- Oncology small‑molecule therapeutics
- Medicinal chemistry and structure‑based design
- In‑silico modelling for infectious diseases
Key Technologies
- Small‑molecule medicinal chemistry
- Structure‑based drug design
- In‑silico pathogen modelling
- Cell‑based phenotypic screening
News & Updates
Bugworks and GARDP expand strategic partnership to accelerate development of an oral formulation of BWC0977 to treat serious bacterial infections.
Bugworks was awarded as the best emerging innovator of India in the deep science space at the Forbes India Leadership Awards 2025.
Bugworks was featured in an article by Willow Shah-Neville for Labiotech titled “Six biotech companies leading the way in India”.
Bugworks was featured in a BBC story titled “India’s ‘blockbuster’ drugs to take on deadly superbugs”.
Bugworks and GARDP expand strategic partnership to accelerate development of an oral formulation of BWC0977 to treat serious bacterial infections.
Bugworks was awarded as the best emerging innovator of India in the deep science space at the Forbes India Leadership Awards 2025.
Bugworks was featured in an article by Willow Shah-Neville for Labiotech titled “Six biotech companies leading the way in India”.
Bugworks was featured in a BBC story titled “India’s ‘blockbuster’ drugs to take on deadly superbugs”.